Header Logo

Connection

Vincent Tam to Microbial Sensitivity Tests

Back to Details
This is a "connection" page, showing publications Vincent Tam has written about Microbial Sensitivity Tests.
Vincent Tam
Connection Strength
6.517
Microbial Sensitivity Tests
  1. In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii. J Glob Antimicrob Resist. 2024 Sep; 38:252-255.
    View in: PubMed
    Score: 0.885
  2. Alternative iron-depleted media for cefiderocol susceptibility testing. Int J Antimicrob Agents. 2024 Jul; 64(1):107193.
    View in: PubMed
    Score: 0.874
  3. Comparison of cefiderocol in-vitro susceptibility testing modalities. J Glob Antimicrob Resist. 2024 Jun; 37:100-101.
    View in: PubMed
    Score: 0.868
  4. Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection. Antimicrob Agents Chemother. 2024 11 06; 68(11):e0089824.
    View in: PubMed
    Score: 0.225
  5. Growth of Acinetobacter baumannii impacted by iron chelation. Lett Appl Microbiol. 2023 Feb 16; 76(2).
    View in: PubMed
    Score: 0.201
  6. Clinical and genomic analysis of virulence-related genes in bloodstream infections caused by Acinetobacter baumannii. Virulence. 2022 Dec; 13(1):1920-1927.
    View in: PubMed
    Score: 0.198
  7. Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae. J Antimicrob Chemother. 2022 10 28; 77(11):3130-3137.
    View in: PubMed
    Score: 0.197
  8. An integrated approach to evaluate different tetracycline derivatives for formulary decisions. Am J Health Syst Pharm. 2022 03 07; 79(6):467-471.
    View in: PubMed
    Score: 0.188
  9. Clinical outcomes of cystic fibrosis patients with Pseudomonas aeruginosa bloodstream infection. J Glob Antimicrob Resist. 2022 06; 29:551-552.
    View in: PubMed
    Score: 0.185
  10. Hydrolytic activity of KPC-producing Klebsiella pneumoniae clinical isolates. J Chemother. 2022 09; 34(5):345-346.
    View in: PubMed
    Score: 0.184
  11. Optimizing pharmacokinetics/pharmacodynamics of ?-lactam/?-lactamase inhibitor combinations against high inocula of ESBL-producing bacteria. J Antimicrob Chemother. 2021 01 01; 76(1):179-183.
    View in: PubMed
    Score: 0.173
  12. MIC profiling of ceftazidime/avibactam against two carbapenemase-producing Klebsiella pneumoniae isolates. J Glob Antimicrob Resist. 2020 12; 23:385-387.
    View in: PubMed
    Score: 0.172
  13. The impact of serum protein binding on bacterial killing of minocycline. J Glob Antimicrob Resist. 2020 06; 21:252-254.
    View in: PubMed
    Score: 0.161
  14. Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-?-Lactamase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019 02; 63(2).
    View in: PubMed
    Score: 0.152
  15. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing bloodstream isolates of Klebsiella pneumoniae in a tertiary care hospital. J Chemother. 2018 Apr; 30(2):115-119.
    View in: PubMed
    Score: 0.139
  16. Ceftolozane/tazobactam activity against meropenem-non-susceptible Pseudomonas aeruginosa bloodstream infection isolates. J Glob Antimicrob Resist. 2017 12; 11:154-155.
    View in: PubMed
    Score: 0.139
  17. The complexity of minocycline serum protein binding. J Antimicrob Chemother. 2017 06 01; 72(6):1632-1634.
    View in: PubMed
    Score: 0.135
  18. Determining ?-lactam exposure threshold to suppress resistance development in Gram-negative bacteria. J Antimicrob Chemother. 2017 05 01; 72(5):1421-1428.
    View in: PubMed
    Score: 0.134
  19. Pharmacokinetics and Pharmacodynamics of Minocycline against Acinetobacter baumannii in a Neutropenic Murine Pneumonia Model. Antimicrob Agents Chemother. 2017 05; 61(5).
    View in: PubMed
    Score: 0.134
  20. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015 May; 59(5):2720-5.
    View in: PubMed
    Score: 0.116
  21. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May; 45(5):541-4.
    View in: PubMed
    Score: 0.115
  22. In vitro ceftriaxone susceptibility in methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1370.
    View in: PubMed
    Score: 0.113
  23. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J Infect Dis. 2013 Mar 01; 207(5):786-93.
    View in: PubMed
    Score: 0.099
  24. In vitro pharmacodynamics of AZD5206 against Staphylococcus aureus. Antimicrob Agents Chemother. 2013 Feb; 57(2):1062-4.
    View in: PubMed
    Score: 0.099
  25. In vitro activity of MK-7655, a novel ?-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob Agents Chemother. 2012 Jul; 56(7):3753-7.
    View in: PubMed
    Score: 0.095
  26. Novel modeling framework to guide design of optimal dosing strategies for ?-lactamase inhibitors. Antimicrob Agents Chemother. 2012 May; 56(5):2237-40.
    View in: PubMed
    Score: 0.094
  27. The emergence of cefiderocol resistance in Pseudomonas aeruginosa from a heteroresistant isolate during prolonged therapy. Antimicrob Agents Chemother. 2024 01 10; 68(1):e0100923.
    View in: PubMed
    Score: 0.053
  28. A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE)?bloodstream infections. Int J Antimicrob Agents. 2023 Apr; 61(4):106760.
    View in: PubMed
    Score: 0.050
  29. Deciphering longitudinal optical-density measurements to guide clinical dosing regimen design: A model-based approach. Comput Methods Programs Biomed. 2022 Dec; 227:107212.
    View in: PubMed
    Score: 0.049
  30. In vitro activity of tigecycline and proteomic analysis of tigecycline adaptation strategies in clinical Enterococcus faecalis isolates from China. J Glob Antimicrob Resist. 2022 09; 30:66-74.
    View in: PubMed
    Score: 0.048
  31. New ?-Lactam-?-Lactamase Inhibitor Combinations. Clin Microbiol Rev. 2020 12 16; 34(1).
    View in: PubMed
    Score: 0.043
  32. Prolonged Versus Intermittent Infusion of ?-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Clin Pharmacokinet. 2020 10; 59(10):1237-1250.
    View in: PubMed
    Score: 0.043
  33. The Fluorocycline TP-271 Is Efficacious in Models of Aerosolized Francisella tularensis SCHU S4 Infection in BALB/c Mice and Cynomolgus Macaques. Antimicrob Agents Chemother. 2017 08; 61(8).
    View in: PubMed
    Score: 0.034
  34. Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. Antimicrob Agents Chemother. 2017 07; 61(7).
    View in: PubMed
    Score: 0.034
  35. Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis. Antimicrob Agents Chemother. 2017 06; 61(6).
    View in: PubMed
    Score: 0.034
  36. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015 Feb; 15(2):225-34.
    View in: PubMed
    Score: 0.028
  37. An evaluation of multiple phenotypic screening methods for Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. J Infect Chemother. 2014 Mar; 20(3):224-7.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.